Explain this page
Arphra AIPlain-English read on Revolution Medicines, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $165.33 (+10.79%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.15% | -6.70% | +4.72% | +51.66% | +87.38% | +87.36% | +267.74% | +454.55% | +367.51% | +416.37% | +416.37% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$149.00
Bid
$148.51
7 sh
Ask
$150.00
184 sh
Spread
$1.490
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?zacks.com·Jun 05, 2026
- Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.fool.com·Jun 05, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancerglobenewswire.com·May 06, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progressglobenewswire.com·May 06, 2026
- US FDA authorizes early access to Revolution's pancreatic cancer pillreuters.com·May 01, 2026
Peers
No peer list available for RVMD.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|